metastatic castration-resistant prostate cancer
FDA Expands Pluvicto’s Metastatic Castration-Resistant Prostate Cancer Indication
The FDA expanded the indication for Pluvicto to include adults with PSMA-positive metastatic castration-resistant ...
APRIL 2, 2025
Akeega Plus Prednisone Approved for BRCA-mutated mCRPC
The FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), ...
AUGUST 16, 2023
FDA Grants New Indication for Talzenna with Enzalutamide for HRR Gene-mutated mCRPC
The FDA approved Talzenna with enzalutamide for homologous recombination repair gene-mutated metastatic ...
JUNE 28, 2023
New Indication Granted for Lynparza for BRCA-mutated mCRPC
The FDA granted a new indication for Lynparza with abiraterone and a steroid for adult patients with deleterious or ...
JUNE 2, 2023
Load more